Background The approach for staging gastric adenocarcinoma (GC) has not been well defined, with heterogeneity in the application of staging modalities. Methods Utilizing a RAND/UCLA appropriateness methodology (RAM), a multidisciplinary expert panel of 16 physicians scored 84 GC staging scenarios. Appropriateness was scored from 1 to 9. Median appropriateness scores from 1 to 3 were considered inappropriate, 4-6 uncertain, and 7-9 appropriate. Agreement was reached when 12 or more of 16 panelists scored the scenario similarly. Appropriate scenarios were subsequently scored for necessity.
Introduction
Management of gastric adenocarcinoma (GC) is complex and resource intensive [1] . Decisions require planning by a multidisciplinary team. The foundation of treatment planning is accurate staging of tumor depth (T), regional lymph node (LN) involvement (N), and distant metastases (M) [2] . Several techniques are available for evaluation of GC, including esophagogastroduodenoscopy (EGD) and biopsy, computed tomography (CT) scan of the chest, abdomen, and pelvis, positron emission tomography (PET) scan, endoscopic ultrasound (EUS) with fine-needle aspiration (FNA), staging laparoscopy, and peritoneal cytology.
Although guidelines exist describing the workup and treatment for GC [3] [4] [5] [6] , the application of staging techniques is not uniform [7] [8] [9] . Furthermore, existing guidelines do not convey the relative importance of individual tests, nor do they comment how these tests should be performed. Standardization of staging of GC could lead to the most appropriate stage-specific treatment and improved outcomes. Therefore, we performed a RAND/UCLA appropriateness methodology (RAM) study to clarify appropriate and necessary processes of care in the pretreatment staging of GC.
Methods
The RAM is a well-described modified Delphi methodology [10] [11] [12] [13] [14] , developed to determine appropriate care in situations where strong, evidence-based guidelines are not possible. Briefly, members for an expert panel were recruited. From the applicants, a multidisciplinary expert panel of 16 physicians from six countries was assembled (ESM Appendix 1). A detailed literature review [15] [16] [17] [18] was conducted to synthesize the latest evidence regarding staging and provided to the panelists.
Matrices of clinical scenarios regarding staging were written, pilot tested, and revised to a total of 84 scenarios. These scenarios were sent to the panelists, who scored them for appropriateness, which is defined as ''the expected health benefit of an intervention exceeding the expected negative consequences by a wide enough margin that the procedure is worth doing, regardless of cost'' [19] . Appropriateness was scored from 1 (highly inappropriate) to 9 (highly appropriate) [13] . Panelists returned their scores and data were analyzed for areas of agreement.
The panel met in Toronto, Ontario, October 22-24, 2010, for discussion of the scenarios and scoring, focusing on areas of disagreement. Some scenarios were rewritten for clarification. All scenarios were confidentially rescored. During final analysis, scenarios were classified as appropriate when median appropriateness scores (MAS) was 7-9, with agreement; inappropriate when MAS was 1-3, with agreement; and uncertain when MAS was 4-6, with agreement. Agreement was met when B4 panelists rated outside the 3-point region containing the median (i.e., 1-3, 4-6, 7-9). Disagreement occurred when C4 panelists rated in each extreme 3-point region (i.e., 1-3, 7-9). The level of agreement was indeterminate when it failed to satisfy either of these criteria [13] .
When a scenario was agreed to be appropriate, it was subsequently scored for necessity, defined as ''the expected health benefits exceeding the expected harms by such a margin that the service must be offered to the patient'' [13, 20] . In the final classification each statement could be labeled as (1) necessary (i.e., appropriate, and necessary); (2) appropriate, but not necessary; (3) uncertain; (4) inappropriate; (5) indeterminate; or (6) disagreement. The study design was approved by the Research Ethics Board, Sunnybrook Health Sciences Centre.
Results
Final levels of agreement and MAS or median necessity scores (MNS) are summarized in Tables 1, 2 , and 3, and ESM Appendices 2-4. When a scenario is necessary, only the MNS is shown. For all other final levels of agreement, the MAS is shown. Major themes include (1) general staging, (2) endoscopy, (3) radiologic assessment, (4) EUS, and (5) laparoscopy.
Panelists agreed it is necessary that TNM stage be determined preoperatively (ESM Appendix 2). Panelists thought it is necessary for all patients to receive an EGD before surgery, and endoscopists should biopsy the tumor and document its (1) size, (2) appearance, (3) location, (4) distance from the gastroesophageal junction (GEJ), (5) GEJ involvement, (6) esophageal involvement, and (7) duodenal involvement. Before resection, surgeons should repeat the EGD if original EGD reports are unclear (Table 1) .
Panelists agreed it is necessary to (1) obtain CT-abdomen/pelvis and (2) perform CT scans using multidetector CT scanners (MDCT) with 5-mm slices. Panelists agreed it is appropriate, but not necessary, to perform (1) CT-chest, and (2) CT scans with MDCT capable of 64 slices (Table 2) . Panelists agreed it is uncertain whether PET scan should be performed for preoperative assessment (ESM Appendix 3).
The panel agreed EUS is appropriate before endoscopic resection, but not necessary. The role of EUS before surgical resection is indeterminate (ESM Appendix 4).
Panelists agreed laparoscopy is necessary, in patients planned for resection of suspected T3-4 lesions, and for planned multivisceral resections (Table 3) . Panelists agreed it is appropriate, but not necessary, to perform laparoscopy on patients whose pretreatment imaging shows positive LNs. During laparoscopy, the panel agreed it is necessary to visually inspect the (1) stomach, (2) diaphragm, (3) liver, and (4) ovaries. Panelists agreed that sending ascites/peritoneal washings for Papanicolaou stain examination was appropriate during laparoscopy, but not necessary.
Discussion GC is relatively rare in Western countries, where, despite existing guidelines [3] [4] [5] [6] , there is a lack of consistency in pretreatment staging [7, 8] . Determination of appropriate and necessary practices may help create uniformity in the pretreatment staging of GC. Although the wording for the scenarios was ''preoperative,'' patients under consideration for a neoadjuvant chemotherapy approach should be staged before treatment initiation. Patients who are not operative candidates, or have evidence of metastatic disease on The endoscopist should document tumor size Necessary (7.0)
The endoscopist should describe the tumor Necessary (8.0)
The endoscopist should biopsy the tumor Necessary (9.0)
The endoscopist should biopsy normal tissue Indeterminate (5.0)
The endoscopist should describe the tumor location within the stomach Necessary (9.0)
The endoscopist should document the distance from the incisors to the tumor Indeterminate (8.0)
The endoscopist should document the distance from the GE junction to the tumor Necessary (7.0)
The endoscopist should document the distance from the pylorus to the tumor Indeterminate (6.0)
The endoscopist should document GE junction involvement Necessary (8.5)
The endoscopist should document esophageal involvement Necessary (9.0)
The endoscopist should document duodenal involvement Necessary (8.0)
The endoscopist should document retroflexion Appropriate (8.0)
For GE junction tumors, the endoscopist should biopsy normal-appearing tissue proximal to the lesion to evaluate for submucosal spread in the oesophagus Indeterminate (5.5)
For GE junction tumors, the endoscopist should define the tumor by Siewert type Appropriate (8.0)
The endoscopist should tattoo all lesions Indeterminate (4.0)
The endoscopist should tattoo lesions that are flat Indeterminate (6.0)
The endoscopist should tattoo lesions that are \2 cm in diameter Indeterminate (7.0)
The endoscopist should tattoo lesions that are in the proximal stomach Uncertain (5.0)
The endoscopist should tattoo lesions that are in the midbody of the stomach Indeterminate (5.0)
The endoscopist should tattoo lesions that are in the distal stomach Uncertain (5.0)
The endoscopist should tattoo lesions if a laparoscopic resection may be performed Appropriate (7.0)
The endoscopist should tattoo lesions if neoadjuvant chemotherapy may be given Indeterminate (6.0)
The endoscopist should take photographs of the tumor Indeterminate (6.0)
The endoscopist should record a video of the procedure Uncertain (5.0)
The endoscopist should send biopsies for Helicobacter pylori analysis Appropriate (7.0)
Before resection, the surgeon should perform a repeat endoscopy to confirm tumor location for all patients Uncertain (5.0)
Before resection, the surgeon should perform a repeat endoscopy to confirm tumor location of proximal gastric tumors Indeterminate (5.0)
Before resection, the surgeon should perform a repeat endoscopy to confirm tumor location if the original EGD report is unclear
Necessary (8.0)
During endoscopy, 6-8 biopsies of the cancer should be taken for HER-2 testing Indeterminate (5.0)
Results shown as final level of agreement, and the median appropriateness or necessity score on a scale of 1-9. Results in bold indicate agreement was met NA not applicable, GE gastroesophageal, EGD esophagogastroduodenoscopy Appropriate staging of gastric cancer 379 Table 3 Appropriateness and necessity of practices in pretreatment staging laparoscopy and peritoneal lavage in the staging of gastric adenocarcinoma Scenario: pretreatment staging laparoscopy Final level of agreement A staging laparoscopy should be performed for all patients planned for curative-intent resection of GC Disagreement (6.0) A staging laparoscopy should be performed for patients planned for curative-intent resection of GC with a suspected T1 lesion
Disagreement (3.0)
A staging laparoscopy should be performed for patients planned for curative-intent resection of GC with a suspected T2 lesion Indeterminate (7.5)
A staging laparoscopy should be performed for patients planned for curative-intent resection of GC with a suspected T3 or T4 lesion
Necessary (7.0)
A staging laparoscopy should be performed for patients planned for curative-intent resection of GC if a multivisceral resection is planned
A staging laparoscopy should be performed for patients planned for curative-intent resection of GC when preoperative imaging shows positive lymph nodes
Appropriate (8.0)
A staging laparoscopy should be performed for patients planned for curative-intent resection before initiating perioperative chemotherapy Indeterminate (7.5)
A staging laparoscopy should be performed for patients planned for curative-intent resection who had perioperative chemotherapy after the chemotherapy and before the resection Indeterminate Results shown as final level of agreement, and the median appropriateness or necessity score on a scale of 1-9. Results in bold indicate agreement was met GC gastric adenocarcinoma, IHC immunohistochemistry, PCR polymerase chain reaction, NA not applicable A CT-PELVIS should be performed for preoperative assessment of GC Necessary (7.0)
A CT-CHEST should be performed for preoperative assessment of GC Appropriate (7.5)
A CT scan for preoperative assessment should be performed with a gastric-specific distension/contrast protocol Indeterminate (7.0)
A CT scan for preoperative assessment should be performed with a MDCT with a capability of 4 slices Indeterminate (3.0)
A CT scan for preoperative assessment should be performed with a MDCT with a capability of 16 slices Indeterminate (7.0)
A CT scan for preoperative assessment should be performed with a MDCT with a capability of 64 slices Appropriate (7.5)
A CT scan for preoperative assessment should be performed with a MDCT with 3-mm thickness/slice Indeterminate (7.0)
A CT scan for preoperative assessment should be performed with a MDCT with 5-mm thickness/slice Necessary (7.0)
A CT scan for preoperative assessment should be performed with a MDCT with 7-mm thickness/slice Indeterminate (5.0)
Results shown as final level of agreement, and the median appropriateness or necessity score on a scale of 1-9. Results in bold indicate agreement was met CT computed tomography, GC gastric adenocarcinoma, NA not applicable, MDCT multidetector computed tomography physical examination may not require these staging modalities.
The foundation of the pretreatment workup is determination of TNM stage, so patients can be allocated toward the most appropriate stage-specific treatment. As expected, panelists agreed determination of T, N, and M is necessary for optimal treatment planning. The highest necessity score was for determination of M-stage, reflecting an important dichotomy in treatment decision making, as M1 patients are not appropriate candidates for curative-intent surgery [4, 5, 21] . Knowledge of metastatic disease would spare the patient an unnecessary laparotomy or futile resection, both of which are associated with high rates of morbidity and mortality [8, 9, 21] .
EGD is the primary diagnostic investigation for evaluation of suspected GC. When performed properly, it provides valuable information such as location and duodenal and esophageal involvement and facilitates acquisition of biopsies [5] . Other guidelines strongly support the use of EGD during workup of GC. However, only 20-42 % of EGD reports are deemed adequate for surgical planning. Thus, surgeons are highly likely to repeat EGD before resection [22] .There is a paucity in the literature regarding the quality of EGD reports. Existing guidelines do not comment on what constitutes a complete EGD report [4] [5] [6] . Our panelists have provided recommendations for information to be included in EGD reports for GC.
CT scan is widely employed for pretreatment staging of GC. It is useful for examining local tumor extension, regional LN involvement, and the presence of peritoneal dissemination, liver metastases, and other sites of metastatic spread. The emphasis the panelists have placed on determining M-stage preoperatively underscores the importance of obtaining a staging CT scan. Previously established guidelines state that CT-abdomen is the modality of choice for the evaluation of local extension and distant metastases [3, 4] . Our panelists agreed, and additionally thought that evaluation of the pelvis is necessary for thorough evaluation of intraabdominal spread. CT-chest was considered appropriate to accurately stage proximal tumors and could be applied selectively, as the incidence of lung metastases is low [23] .
EUS allows evaluation of the individual layers of the gastric wall [24, 25] , with an overall pooled accuracy of 75 % [16] . Some guidelines support the use of EUS for staging of esophageal and GEJ tumors [4] [5] [6] , to determine which patients may benefit from neoadjuvant regimens [5] . Otherwise, there is a lack of agreement between established guidelines concerning the utility of EUS, making its applicability uncertain [3] [4] [5] . Our panelists did not agree on the appropriateness of EUS before surgical resection, likely because EUS often does not change management strategies for resectable tumors by radiologic staging.
Laparoscopy is an effective, highly accurate modality for identifying metastasis in asymptomatic patients who would not benefit from resection [9, 17, 26, 27] . However, consistent with other groups, the panel noted that laparoscopy should be selectively applied to suspected T3-4 tumors, as the diagnostic yield of laparoscopy for suspected early GC is low because metastases are rare [28] ; this is in agreement with existing guidelines [29] . Additionally, the panelists offer guidelines regarding content of the laparoscopy.
Positive peritoneal lavage is a poor prognostic indicator [30] ; however, its value among practice guidelines remains controversial [3, 4] . Our panelists thought that performing peritoneal lavage is appropriate, but not necessary. An argument can be made, however, for performing peritoneal lavage, as the added time and morbidity to do so during a laparoscopy are insignificant. Future studies may examine how often these staging maneuvers are performed for GC patients.
Conclusions
We used a RAND/UCLA method to establish appropriate and necessary practices in the pretreatment staging of GC, as well as how these investigations can optimally be performed. Accurate staging is of paramount importance in stratifying patients into optimal stage-specific treatments to maximize survival. The panel's recommendations are useful guidelines when considering which investigations to employ in pretreatment staging.
